Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

  
lung cancer
Fosun's ALK/ROS1 inhibitor meets primary endpoint in Phase III for ALK+ advanced NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D